Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Global Blood Therapeutics (GBT) today and set a price target of $55. The company’s shares closed yesterday at $40.95.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of 7.9% and a 55.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Alexion Pharmaceuticals, and Denali Therapeutics Inc.
Currently, the analyst consensus on Global Blood Therapeutics is a Strong Buy with an average price target of $90.89.
See today’s analyst top recommended stocks >>
Based on Global Blood Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $43.07 million. In comparison, last year the company had a GAAP net loss of $28.56 million.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
